Development of standard clinical endpoints for use in dengue interventional trials

• Published in: PLoS neglected tropical diseases 2018-10, Vol.12 (10), p.e0006497-e0006497
• Main Authors: Tomashek, Kay M, Wills, Bridget, See Lum, Lucy Chai, Thomas, Laurent, Durbin, Anna, Leo, Yee-Sin, de Bosch, Norma, Rojas, Elsa, Hendrickx, Kim, Erpicum, Martin, Agulto, Liane, Jaenisch, Thomas, Tissera, Hasitha, Suntarattiwong, Piyarat, Collers, Beth Ann, Wallace, Derek, Schmidt, Alexander C, Precioso, Alexander, Narvaez, Federico, Thomas, Stephen J, Edelman, Robert, Siqueira, João Bosco, Cassetti, M Cristina, Dempsey, Walla, Gubler, Duane J
• Format: Article
• Language: English
• Subjects: Biology and Life Sciences; Bleeding; Clinical trials; Data collection; Dengue; Dengue fever; Dengue hemorrhagic fever; Deployment; Disease control; Drug development; Heart diseases; Hemodynamics; Hepatitis; Hospitals; Human diseases; Infectious diseases; Liver diseases; Medical research; Medicine and Health Sciences; Myocarditis; Neurological diseases; Occupational health; Pediatrics; Platelets; Product safety; Public health; Society; Standardization; Thrombocytopenia; Tropical diseases; Vaccines; Vector-borne diseases; Viral diseases; Viral infections
• ISSN: 1935-2735; 1935-2727; 1935-2735
• DOI: 10.1371/journal.pntd.0006497

Dengue is a major public health problem worldwide. Although several drug candidates have been evaluated in randomized controlled trials, none has been effective and at present, early recognition of severe dengue and timely supportive care are used to reduce mortality. While the first dengue vaccine was recently licensed, and several other candidates are in late stage clinical trials, future decisions regarding widespread deployment of vaccines and/or therapeutics will require evidence of product safety, efficacy and effectiveness. Standard, quantifiable clinical endpoints are needed to ensure reproducibility and comparability of research findings. To address this need, we established a working group of dengue researchers and public health specialists to develop standardized endpoints and work towards consensus opinion on those endpoints. After discussion at two working group meetings and presentations at international conferences, a Delphi methodology-based query was used to finalize and operationalize the clinical endpoints. Participants were asked to select the best endpoints from proposed definitions or offer revised/new definitions, and to indicate whether contributing items should be designated as optional or required. After the third round of inquiry, 70% or greater agreement was reached on moderate and severe plasma leakage, moderate and severe bleeding, acute hepatitis and acute liver failure, and moderate and severe neurologic disease. There was less agreement regarding moderate and severe thrombocytopenia and moderate and severe myocarditis. Notably, 68% of participants agreed that a 50,000 to 20,000 mm3 platelet range be used to define moderate thrombocytopenia; however, they remained divided on whether a rapid decreasing trend or one platelet count should be case defining. While at least 70% agreement was reached on most endpoints, the process identified areas for further evaluation and standardization within the context of ongoing clinical studies. These endpoints can be used to harmonize data collection and improve comparability between dengue clinical trials.